Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura W Dillon

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant-ReplyGege Gui, Laura W Dillon, Christopher S Hourigan
British Journal of Haematology|December 6, 2019
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemiaJack Ghannam, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid MalignancyGege Gui, Laura W Dillon, Christopher S Hourigan
Journal of Thyroid Research|July 5, 2012
The role of fragile sites in sporadic papillary thyroid carcinomaLaura W Dillon, Christine E Lehman, Yuh-Hwa Wang
Current Genomics|February 3, 2011
DNA instability at chromosomal fragile sites in cancerLaura W Dillon, Allison A Burrow, Yuh-Hwa Wang
Best Practice & Research. Clinical Haematology|June 23, 2023
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemiaZoë C Wong, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Medicine|September 20, 2017
Technical Advances in the Measurement of Residual Disease in Acute Myeloid LeukemiaGregory W Roloff, Catherine Lai, Christopher S Hourigan, et al.
EMBO Reports|November 6, 2013
Human Primpol1: a novel guardian of stalled replication forksJun-Sub Im, Kyung Yong Lee, Laura W Dillon, et al.
Carcinogenesis|January 11, 2017
DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangementsChristine E Lehman, Laura W Dillon, Yuri E Nikiforov, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2024
<i>TP53</i> mutation screening for patients at risk of myeloid malignancyDevdeep Mukherjee, Rialnat A Lawal, Courtney D Fitzhugh, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant-ReplyGege Gui, Laura W Dillon, Christopher S Hourigan
British Journal of Haematology|December 6, 2019
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemiaJack Ghannam, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid MalignancyGege Gui, Laura W Dillon, Christopher S Hourigan
Journal of Thyroid Research|July 5, 2012
The role of fragile sites in sporadic papillary thyroid carcinomaLaura W Dillon, Christine E Lehman, Yuh-Hwa Wang
Current Genomics|February 3, 2011
DNA instability at chromosomal fragile sites in cancerLaura W Dillon, Allison A Burrow, Yuh-Hwa Wang
Best Practice & Research. Clinical Haematology|June 23, 2023
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemiaZoë C Wong, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Medicine|September 20, 2017
Technical Advances in the Measurement of Residual Disease in Acute Myeloid LeukemiaGregory W Roloff, Catherine Lai, Christopher S Hourigan, et al.
EMBO Reports|November 6, 2013
Human Primpol1: a novel guardian of stalled replication forksJun-Sub Im, Kyung Yong Lee, Laura W Dillon, et al.
Carcinogenesis|January 11, 2017
DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangementsChristine E Lehman, Laura W Dillon, Yuri E Nikiforov, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2024
<i>TP53</i> mutation screening for patients at risk of myeloid malignancyDevdeep Mukherjee, Rialnat A Lawal, Courtney D Fitzhugh, et al.
Pageof 5